Balance Sheet
Accounts PayablesCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Receivables - Net: 2017-2025

  • Dr Reddys Laboratories' Receivables - Net rose 9.87% to $1.1 billion in Q1 2025 from the same period last year, while for Mar 2025 it was $1.1 billion, marking a year-over-year increase of 9.87%. This contributed to the annual value of $1.1 billion for FY2025, which is 9.87% up from last year.
  • Dr Reddys Laboratories' Receivables - Net amounted to $1.1 billion in Q1 2025, which was up 9.87% from $963.0 million recorded in Q1 2024.
  • In the past 5 years, Dr Reddys Laboratories' Receivables - Net ranged from a high of $1.1 billion in Q1 2025 and a low of $679.0 million during Q1 2021.
  • Its 3-year average for Receivables - Net is $967.7 million, with a median of $963.0 million in 2024.
  • Data for Dr Reddys Laboratories' Receivables - Net shows a peak YoY grew of 29.60% (in 2022) over the last 5 years.
  • Over the past 5 years, Dr Reddys Laboratories' Receivables - Net (Quarterly) stood at $679.0 million in 2021, then rose by 29.60% to $880.0 million in 2022, then increased by 0.23% to $882.0 million in 2023, then climbed by 9.18% to $963.0 million in 2024, then rose by 9.87% to $1.1 billion in 2025.
  • Its Receivables - Net was $1.1 billion in Q1 2025, compared to $963.0 million in Q1 2024 and $882.0 million in Q1 2023.